Allakos (NASDAQ:ALLK) Stock Rating Lowered by Citizens Jmp

Citizens Jmp downgraded shares of Allakos (NASDAQ:ALLK) from a strong-buy rating to a hold rating in a report published on Monday morning,Zacks.com reports.

Allakos Trading Up 9.1 %

NASDAQ:ALLK opened at $0.26 on Monday. The company has a market cap of $23.04 million, a P/E ratio of -0.13 and a beta of 0.86. Allakos has a twelve month low of $0.23 and a twelve month high of $1.69. The company’s 50-day moving average price is $1.04 and its 200-day moving average price is $0.90.

Allakos (NASDAQ:ALLK) last issued its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. On average, analysts expect that Allakos will post -1.16 earnings per share for the current year.

Hedge Funds Weigh In On Allakos

Hedge funds have recently bought and sold shares of the company. Cubist Systematic Strategies LLC purchased a new stake in shares of Allakos during the 2nd quarter worth $55,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Allakos during the second quarter worth about $112,000. Point72 DIFC Ltd purchased a new stake in shares of Allakos in the 2nd quarter valued at about $25,000. GSA Capital Partners LLP boosted its position in shares of Allakos by 11.9% in the 3rd quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock valued at $519,000 after purchasing an additional 84,750 shares during the period. Finally, FMR LLC boosted its position in shares of Allakos by 14.6% in the 3rd quarter. FMR LLC now owns 5,370,247 shares of the company’s stock valued at $3,508,000 after purchasing an additional 685,623 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.